These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 1431243)
21. Domain swapping reveals complement control protein modules critical for imparting cofactor and decay-accelerating activities in vaccinia virus complement control protein. Ahmad M; Raut S; Pyaram K; Kamble A; Mullick J; Sahu A J Immunol; 2010 Nov; 185(10):6128-37. PubMed ID: 20956343 [TBL] [Abstract][Full Text] [Related]
22. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation. Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650 [TBL] [Abstract][Full Text] [Related]
23. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. Brown EJ; Ramsey J; Hammer CH; Frank MM J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833 [TBL] [Abstract][Full Text] [Related]
24. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Ebanks RO; Isenman DE Mol Immunol; 1996 Feb; 33(3):297-309. PubMed ID: 8649451 [TBL] [Abstract][Full Text] [Related]
25. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. Fujita T; Inoue T; Ogawa K; Iida K; Tamura N J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886 [TBL] [Abstract][Full Text] [Related]
26. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b. Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864 [TBL] [Abstract][Full Text] [Related]
27. Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity. Bernet J; Ahmad M; Mullick J; Panse Y; Singh AK; Parab PB; Sahu A Vaccine; 2011 Oct; 29(43):7435-43. PubMed ID: 21803094 [TBL] [Abstract][Full Text] [Related]
28. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement. Rawal N; Rajagopalan R; Salvi VP J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. Medof ME; Kinoshita T; Nussenzweig V J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120 [TBL] [Abstract][Full Text] [Related]
30. Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H. Blom AM; Kask L; Ramesh B; Hillarp A Arch Biochem Biophys; 2003 Oct; 418(2):108-18. PubMed ID: 14522582 [TBL] [Abstract][Full Text] [Related]
31. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway). Thielens NM; Colomb MG Eur J Immunol; 1986 Jun; 16(6):617-22. PubMed ID: 3487454 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase. Strunk RC; Webster RO Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899 [TBL] [Abstract][Full Text] [Related]
33. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor. Mold C; Walter EI; Medof ME J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein. Saint-Remy JM Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450 [TBL] [Abstract][Full Text] [Related]
35. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. Avirutnan P; Fuchs A; Hauhart RE; Somnuke P; Youn S; Diamond MS; Atkinson JP J Exp Med; 2010 Apr; 207(4):793-806. PubMed ID: 20308361 [TBL] [Abstract][Full Text] [Related]
36. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Rosengard AM; Alonso LC; Korb LC; Baldwin WM; Sanfilippo F; Turka LA; Ahearn JM Mol Immunol; 1999 Jul; 36(10):685-97. PubMed ID: 10509819 [TBL] [Abstract][Full Text] [Related]
37. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase. Sobel AT; Cooper NR; Schreiber RD J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421 [TBL] [Abstract][Full Text] [Related]
38. Formation of high affinity C5 convertase of the classical pathway of complement. Rawal N; Pangburn MK J Biol Chem; 2003 Oct; 278(40):38476-83. PubMed ID: 12878586 [TBL] [Abstract][Full Text] [Related]
39. The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases. Qiu WQ; Luo S; Ma SA; Saminathan P; Li H; Gunnersen JM; Gelbard HA; Hammond JW Front Immunol; 2021; 12():607641. PubMed ID: 33936031 [TBL] [Abstract][Full Text] [Related]
40. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]